Ridgetech Inc Dossier
Qualitative Analysis
Business overview
Ridgetech Inc. (formerly known as China Jo-Jo Drugstores, Inc.) operates as an online and offline wholesale distributor of pharmaceutical and other healthcare products in the People's Republic of China. Following the strategic divestiture of its retail pharmacy operations in February 2025, the company refocused its business model entirely on wholesale distribution. It operates primarily through its Drug Wholesale and Online Pharmacy segments, which include its wholly owned subsidiary Allright (Hangzhou) Internet Technology Co., Ltd., a proprietary online pharmaceutical distribution platform. The company distributes a broad range of products including prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines (TCM), personal and family care products, medical devices, health food, cosmetics, and daily necessities.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A comprehensive strategy centering on supply chain integration by leveraging the company's wholesale distribution network, B2B platform, and franchise system. It positions offline wholesale (Zhejiang Jiuxin Medicine Co., Ltd.) and online wholesale (Allright) as parallel growth engines.
Expected impact: Aims to achieve parallel breakthroughs in business model innovation and value creation, accelerating the transition from a traffic-driven to a value-driven business model across China's pharmaceutical supply chain.
Systematically introducing Jiuxin Medicine's offline supply chain products onto the Allright online platform, integrating procurement and sales processes, conducting joint recruitment, and implementing data sharing between the two platforms.
Expected impact: Reduces distribution layers, improves response speed and operational agility, and expands Allright's customer base to over 300,000.
Deepening strategic cooperation with core suppliers, reinforcing exclusive agency resources, expanding distribution of high-margin domestic and international brands, implementing full-process controls for agency products, and optimizing rebate settlement mechanisms.
Expected impact: Aims to enhance full-chain competitiveness, reinforce compliance management, and strengthen financial risk control capabilities.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To expand into both online and offline wholesale distribution of pharmaceutical and healthcare products in China, shifting resources away from the high-cost retail drugstore segment.
Financial impact: Contributed $11.13 million in online platform revenue with a 7.0% gross margin for the six months ended September 30, 2025, helping offset declines in offline wholesale.